logo

Epix Pharmaceuticals, Inc. (EPIX)



Trade EPIX now with
  Date
  Headline
9/13/2022 7:03:54 AM ESSA Pharma Appoints Philip Kantoff To Board
8/4/2022 7:56:34 AM ESSA Pharma Q2 Net Loss Flat At $8.8 Mln
5/10/2022 7:42:45 AM ESSA Pharma Q2 Loss/shr $0.25 Vs Loss/shr $0.36 Prior Year
3/9/2022 11:40:13 PM ESSA Pharma Reports Results Of Annual General Meeting Of Shareholders
10/7/2021 9:21:33 AM ESSA Pharma Announces Presentation Of Preclinical Data Characterizing Mechanism Of Action Of EPI-7386
8/16/2021 7:05:17 AM ESSA Pharma Q3 Net Loss $8.8 Mln Vs. Net Loss $4.9 Mln Last Year
4/28/2021 7:19:15 AM ESSA Collaborates With Bayer To Evaluate Combination Of EPI-7386 And Darolutamide In MCRPC Cancer
2/17/2021 10:58:04 PM ESSA Pharma Announces Pricing Of Public Offering Of 4.83 Mln Common Shares At $27/Shr
2/11/2021 8:11:43 AM ESSA Pharma Presents Favorable Initial Phase 1 Pharmacology Data Of EPI-7386 For Advanced Forms Of Prostate Cancer
2/11/2021 7:58:19 AM ESSA Pharma Q1 Net Loss $6.5 Mln Or $0.20/shr Vs Loss Of $4.6 Mln Or $0.22/shr Prior Year
1/13/2021 7:23:20 AM ESSA Pharma Enters Clinical Collaboration And Supply Agreement With Janssen Research & Development, LLC
1/13/2021 7:18:49 AM ESSA, Janssen To Evaluate EPI-7386 Combination For Patients With Metastatic Castration-Resistant Prostate Cancer
1/13/2021 7:01:56 AM ESSA Pharma Enters Clinical Collaboration With Janssen To Evaluate EPI-7386 Combination For Patients With MCRPC